Head-to-head · Value Score
Vitara RX vs Peter MD
Two GLP-1 deals, scored on the same six factors. Vitara RX lands a Value Score of 91, Peter MD a 74. Here's who gives you the honest lower price — and where each one bites back.
Vitara RX
#4 · Grade A · Best Value
Est. first month
$99/mo
Save ~93% vs brand-namePeter MD
#105 · Grade C+ · Watch List
Est. first month
$149/mo
Save ~89% vs brand-nameThe verdict
Vitara RX takes it on Value Score, 91 to 74 — an est. $99/mo first month, with no teaser step-up baked in. Peter MD isn't out of it: Shoppers who want to consolidate GLP-1 with other treatments — testosterone, NAD+, sermorelin, ED or hair loss — on a single account, and who will budget for tirzepatide's $249/mo rate from month two rather than anchoring on the $149 intro.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Vitara RX | Peter MD |
|---|---|---|
| Value Score | 91 (A) | 74 (C+) |
| Est. first month | $99/mo | $149/mo |
| Save vs brand-name | ~93% | ~89% |
| Semaglutide | $99/mo | $149/mo first-time (Level 1), $139/mo returning (Level 2) — compounded w/ B12 |
| Tirzepatide | $149/mo | $149 first month, then $249/mo billed quarterly (60mg) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | 49 states | Nationwide, but restrictions vary by treatment — AL/ID excluded across the board; tirzepatide also excluded in AR/CA/MI/NC/TX; B-12 also excluded in AR/CA/KY/LA/SC |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Vitara RX
VitaraRx is a direct-to-consumer telehealth marketplace offering compounded semaglutide and tirzepatide at flat per-drug pricing across all doses — no membership or hidden fees.
Why it's a deal
- Among the lowest flat pricing in the market — $99/mo semaglutide and $149/mo tirzepatide, all doses same price
- Names its 503A pharmacy partner (Manifest Pharmacy, Greer SC) — strong supply-chain transparency
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- Covers 49 states with an explicit state list, not vague "most states" language
The fine print
- No corporate legal entity disclosed — only the trade name "VitaraRx"
- No named medical director — all clinical decisions made by independent providers (marketplace model)
- All sales final — no medication returns
- Per-vial mg quantity isn't clearly disclosed, making price comparisons harder
- Doesn't ship to Alaska
Peter MD
A physician-prescribed telehealth account that puts GLP-1 (tirzepatide and compounded semaglutide+B12) alongside TRT, NAD+, sermorelin, ED and hair-loss treatment under one login — with a genuine month-two step-up on tirzepatide to plan around.
Why it's a deal
- Broad product line under one account — TRT, ED, weight loss, GLP-1, NAD+ and men's hair loss — useful if you want more than a single GLP-1 script
- Physician-prescribed and nationwide in structure, not a single-state clinic
- Semaglutide's returning-patient rate ($139/mo) is genuinely cheaper than its first-time rate, not a bait-and-switch in that direction
- Tirzepatide's $149 first month is a real, disclosed price, not a hidden fee
The fine print
- Tirzepatide's real ongoing rate is $249/mo billed quarterly, not the $149 headline — a step-up to budget for, not a flat price
- State restrictions vary by treatment and the full list isn't disclosed on the customer-facing marketing pages — confirm your state for the specific treatment you want before signing up
- Customer reviews are mixed
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Vitara RX is ranked on the Vitara RX alternatives board, and the same list for the other side is on alternatives to Peter MD.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.